Felipe K Hurtado

Felipe K Hurtado

Daiichi-Sankyo Co., Ltd - / Japan
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4507893
まず、山機工株式会社。
person_outline Felipe K Hurtado's MOST POPULAR ARTICLES
1-) Discovery of orally active inhibitors of Brahma homolog (BRM)/SMARCA2 ATPase activity for the treatment of Brahma related gene 1 (BRG1)/SMARCA4-mutant cancers Journal of Medicinal Chemistry 61 (22), 10155-10172, 2018
2-) ★ Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study The Lancet Oncology 22 (12), 1764-1776, 2021
3-) Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients with advanced NSCLC Journal of Clinical Oncology 36 (Suppl 15), Abstr # 9089, 2018
4-) ASCEND-7: Efficacy and safety of ceritinib treatment in patients with ALK-positive non-small cell lung cancer metastatic to the brain and/or leptomeninges Clinical Cancer Research 28 (12), 2506-2516, 2022
5-) Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer Clinical Cancer Research 28 (11), 2313-2320, 2022